Blocking FGFR3 in bladder cancer with FGFR3 activation increased PD-L1 protein levels by altering its ubiquitination process, which in turn, hampered the anticancer activity of CD8+ T cells. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.